Grant: Collaborative Health Research Projects
University of Toronto
$652,575.00
A vascularized human organoid platform for disease modelling and preclinical testing
EF 2020-21
Résumé
Current preclinical models in a large part fail to accurately portray human physiology . On onehand, traditional tissue culture in which cells are grown in monolayer do not recapitulate thecomplex heterogeneity of 3D organs. On the other hand, animal models such as rodents lackmany specific biological features that are unique to humans. Because the models we are_x000d_using to study human disease and predict drug responses are inaccurate, it is inevitable thatthe predictions made will be similarly inaccurate. This observation is reflected in the currentdrug discovery pipeline, as many drugs that are tested using monolayer culture and animal_x000d_models fail in clinical trials due to unforeseen complexities in human patients. To address thisissue, we are seeking to develop a next generation preclinical model of human disease thataccurately recapitulates human physiology. To do this, we link up artificial organ tissues_x000d_derived from human stem cells to living blood vessels. We then deliver through the blood_x000d_vessels nutrients and drug compounds in the same manner that they are delivered in the_x000d_human body. The artificial organs in our system directly mimic physiological organs in termsof morphology, function, and environment thus serving as a powerful tool for drug testing. Toestablish our platform, we have gathered a diverse team of academic researchers includingexperts in health research and engineering and several private sector partners. Together, wewill harness our platform to develop sophisticated models of the brain and gut as well as_x000d_advanced imaging frameworks to monitor drug responses in real time. Considering our teamand expertise, we are thus uniquely poised to drastically improve preclinical drug testing_x000d_efficiency not only in Canada but also for global drug discovery pipelines which as the_x000d_potential to scientifically improve human health.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
549533-2020
Name nom
Attisano, Liliana
Department département
Biochemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
652575
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
5111
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Signal transduction
Research subject fr
Transduction de signal
Installment
inst:1 - 3
Partie
3
Nb partie
3
Application title
A vascularized human organoid platform for disease modelling and preclinical testing
Keyword
NSERC
Application summary
Current preclinical models in a large part fail to accurately portray human physiology . On onehand, traditional tissue culture in which cells are grown in monolayer do not recapitulate thecomplex heterogeneity of 3D organs. On the other hand, animal models such as rodents lackmany specific biological features that are unique to humans. Because the models we are_x000d_using to study human disease and predict drug responses are inaccurate, it is inevitable thatthe predictions made will be similarly inaccurate. This observation is reflected in the currentdrug discovery pipeline, as many drugs that are tested using monolayer culture and animal_x000d_models fail in clinical trials due to unforeseen complexities in human patients. To address thisissue, we are seeking to develop a next generation preclinical model of human disease thataccurately recapitulates human physiology. To do this, we link up artificial organ tissues_x000d_derived from human stem cells to living blood vessels. We then deliver through the blood_x000d_vessels nutrients and drug compounds in the same manner that they are delivered in the_x000d_human body. The artificial organs in our system directly mimic physiological organs in termsof morphology, function, and environment thus serving as a powerful tool for drug testing. Toestablish our platform, we have gathered a diverse team of academic researchers includingexperts in health research and engineering and several private sector partners. Together, wewill harness our platform to develop sophisticated models of the brain and gut as well as_x000d_advanced imaging frameworks to monitor drug responses in real time. Considering our teamand expertise, we are thus uniquely poised to drastically improve preclinical drug testing_x000d_efficiency not only in Canada but also for global drug discovery pipelines which as the_x000d_potential to scientifically improve human health.